Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Cerebrolysin | Humanin | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 10-30 mL daily via intravenous infusion for neurological indications. 5-10 mL for cognitive optimization. | Research indicates dosing remains experimental. Animal studies use 1-10 mcg/day equivalents. Human protocols are not established. |
| Timing | Morning administration preferred for cognitive effects. IV infusion over 15-20 minutes. | No established timing protocol. Morning dosing suggested for neuroprotective applications. |
| Cycle Duration | 10-20 day intensive cycles repeated every 3-6 months. Some protocols use ongoing 3x weekly maintenance. | Experimental — no established cycle lengths. |
| Evidence Level | moderate_human | animal_plus_anecdotal |
Cerebrolysin is a porcine brain-derived peptide preparation containing a standardized mixture of low-molecular-weight neuropeptides (<10 kDa) and free amino acids obtained through enzymatic proteolysis. It exerts multimodal neurotrophic effects by simultaneously upregulating VEGF, BDNF, IGF-1, and NGF while downregulating TNF-alpha. Cerebrolysin increases furin protease concentration, which promotes pro-NGF to mature NGF conversion. It activates TrkB receptor signaling (BDNF/TrkB/CREB pathway), inhibits neuronal apoptosis, reduces microglial activation, and promotes neurogenesis.
Research indicates 10-30 mL daily via intravenous infusion for neurological indications. 5-10 mL for cognitive optimization.
Morning administration preferred for cognitive effects. IV infusion over 15-20 minutes.
10-20 day intensive cycles repeated every 3-6 months. Some protocols use ongoing 3x weekly maintenance.
Humanin is a 24-amino acid mitochondrial-derived peptide encoded by the 16S rRNA gene of mitochondrial DNA. It binds IGFBP-3 with high affinity (via Phe-6), interfering with IGFBP-3 binding to importin-beta and suppressing IGFBP-3-mediated apoptosis. It also inhibits the pro-apoptotic protein Bax (Bcl-2 family), preventing mitochondrial outer membrane permeabilization and intrinsic apoptosis. Humanin and IGFBP-3 synergistically protect neurons from amyloid-beta-induced apoptosis, and it activates the STAT3 and ERK1/2 pathways for cytoprotection.
Research indicates dosing remains experimental. Animal studies use 1-10 mcg/day equivalents. Human protocols are not established.
No established timing protocol. Morning dosing suggested for neuroprotective applications.
Experimental — no established cycle lengths.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →